Seattle Genetics, Inc. has exercised an option to co-develop an additional antibody-drug conjugate (ADC), ASG-15ME, under its existing collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma. ASG-15ME targets the tumor antigen SLITRK6, which is expressed on bladder and lung cancer. Agensys has submitted an IND to the FDA for a Phase I trial of ASG-15ME. Seattle Genetics will make a payment and thereafter fund half of the future development costs for the ASG-15ME program.   ...